CoChat
Sign Up
Cited by 27Multiple Myeloma Research and TreatmentsExtracellular vesicles in diseaseMicroRNA in disease regulation

Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2

Open access
Gu, Jianmei, Wang, Maoye, Wang, Xinfeng, Li, Jiao, Liu, Haiyan, Lin, Zenghua, Yang, Xi, Zhang, Xu +1 more·2022·Frontiers in Cell and Developmental Biology
DOI 10.3389/fcell.2022.862524PMC PMC8921260
Open this paper in CoChat — free accountOpen PDF

Abstract

Bone marrow-derived mesenchymal stem cell (BMSC) is one crucial component of the multiple myeloma (MM) microenvironment and supports the malignant progression of MM. Whether BMSCs act on MM cells via exosomes has not been well characterized. Herein, we used microarrays to screen out differentially expressed miRNAs in BMSCs from patients with MM (MM-MSCs) or benign diseases (BD-MSCs). We found that miR-483-5p was highly expressed in MM-MSCs, which may be transported through exosomes from MM-MSCs to MM cells to increase miR-483-5p expression in them. We then investigated the role and mechanism of miR-483-5p in the aggressive progression of MM in vitro. We verified that miR-483-5p promoted MM cell proliferation and reduced apoptosis. Then we predicted and validated that TIMP2, a tumor suppressor gene, is the downstream target of miR-483-5p in MM. In summary, our study indicated that MM-MSCs promote MM malignant progression via the release of exosomes and regulation of miR-483-5p/TIMP2 axis, suggesting an essential role of BMSCs derived exosomal miRNA in MM and a potential marker for MM diagnosis and therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcell.2022.862524

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Exosomal miR-483-5p produced from bone marrow mesenchymal stromal cells stimulates the tumor suppressor gene TIMP2 to advance the malignant development of multiple myeloma.

    “In addition, investigations demonstrate the importance of exosomal miR-483-5p produced from BM-MSCs in stimulating the tumor suppressor gene TIMP2 to advance the malignant development of MM [270].”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [270]

    The Discussion says exosomal miR-483-5p from MM-MSCs favors multiple myeloma progression, but it does not stimulate TIMP2. The Results section “TIMP2 Is the Target of miR-483-5p” reports that miR-483-5p decreases TIMP2 mRNA and protein expression—the opposite of the claimed mechanism. (LLM, conf=0.93)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 40

  1. Castro‐Vega L. J. Calsina B. Burnichon N. Drossart T. Martínez‐Montes Á. M. Verkarre V. (2020). Overexpression of miR‐483‐5p Is Confined to Metastases and Linked to High Circulating Levels in Patients with Metastatic Pheochromocytoma/paraganglioma. Clin. Translational Med. 10(8), e260. 10.1002/ctm2.260 PMC7752161 33377638 · DOI
  2. Chen Q. Shou P. Zheng C. Jiang M. Cao G. Yang Q. (2016). Fate Decision of Mesenchymal Stem Cells: Adipocytes or Osteoblasts? Cell Death Differ 23(7), 1128– 1139. 10.1038/cdd.2015.168 26868907 PMC4946886 · DOI
  3. Chen Y. Wang H. Zhu S. Lan X. (2020). miR-483-5p Promotes Esophageal Cancer Progression by Targeting KCNQ1. Biochem. Biophysical Res. Commun. 531(4), 615– 621. 10.1016/j.bbrc.2020.07.037 32819715 · DOI
  4. Colombo M. Raposo G. Théry C. (2014). Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. Annu. Rev. Cel Dev. Biol. 30, 255– 289. 10.1146/annurev-cellbio-101512-122326 25288114 · DOI · Paper page
  5. Corrado C. Raimondo S. Saieva L. Flugy A. M. De Leo G. Alessandro R. (2014). Exosome-Mediated Crosstalk Between Chronic Myelogenous Leukemia Cells and Human Bone Marrow Stromal Cells Triggers an Interleukin 8-Dependent Survival of Leukemia Cells. Cancer Lett. 348 (1-2), 71– 76. 10.1016/j.canlet.2014.03.009 24657661 · DOI
  6. Dart A. (2018). Radical Changes. Nat. Rev. Cancer 18(2), 65. 10.1038/nrc.2018.4 29368744 · DOI
  7. Fu H. Tie Y. Xu C. Zhang Z. Zhu J. Shi Y. (2005). Identification of Human Fetal Liver miRNAs by a Novel Method. FEBS Lett. 579(17), 3849– 3854. 10.1016/j.febslet.2005.05.064 15978578 · DOI
  8. Fuhler G. M. Baanstra M. Chesik D. Somasundaram R. Seckinger A. Hose D. (2010). Bone Marrow Stromal Cell Interaction Reduces Syndecan-1 Expression and Induces Kinomic Changes in Myeloma Cells. Exp. Cel Res. 316(11), 1816– 1828. 10.1016/j.yexcr.2010.03.013 20307537 · DOI
  9. Gao X. Zhou J. Wang J. Dong X. Chang Y. Jin Y. (2021). Mechanism of Exosomal miR-155 Derived from Bone Marrow Mesenchymal Stem Cells on Stemness Maintenance and Drug Resistance in Myeloma Cells. J. Orthop. Surg. Res. 16(1), 637. 10.1186/s13018-021-02793-9 34689803 PMC8543846 · DOI
  10. Giannakoulas N. Ntanasis-Stathopoulos I. Terpos E. (2021). The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. Ijms 22(9, 4462). 10.3390/ijms22094462 33923357 PMC8123209 · DOI
  11. Giuliani N. Rizzoli V. Roodman G. D. (2006). Multiple Myeloma Bone Disease: Pathophysiology of Osteoblast Inhibition. Blood 108(13), 3992– 3996. 10.1182/blood-2006-05-026112 16917004 · DOI · Paper page
  12. Gobin E. Bagwell K. Wagner J. Mysona D. Sandirasegarane S. Smith N. (2019). A Pan-Cancer Perspective of Matrix Metalloproteases (MMP) Gene Expression Profile and Their Diagnostic/prognostic Potential. BMC Cancer 19(1), 581. 10.1186/s12885-019-5768-0 31200666 PMC6567474 · DOI
  13. Gu J. Qian H. Shen L. Zhang X. Zhu W. Huang L. (2012). Gastric Cancer Exosomes Trigger Differentiation of Umbilical Cord Derived Mesenchymal Stem Cells to Carcinoma-Associated Fibroblasts through TGF-β/Smad Pathway. PLoS One 7(12), e52465. 10.1371/journal.pone.0052465 23285052 PMC3527492 · DOI
  14. Jiang D. Wu X. Sun X. Tan W. Dai X. Xie Y. (2022). Bone Mesenchymal Stem Cell-Derived Exosomal microRNA-7-5p Inhibits Progression of Acute Myeloid Leukemia by Targeting OSBPL11. J. Nanobiotechnol 20(1), 29. 10.1186/s12951-021-01206-7 PMC8744354 35012554 · DOI
  15. Jin J. Cheng S. Wang Y. Wang T. Zeng D. Li Z. (2019). SRC3 Expressed in Bone Marrow Mesenchymal Stem Cells Promotes the Development of Multiple Myeloma. Acta Biochim. Biophys. Sin (Shanghai) 51(12), 1258– 1266. 10.1093/abbs/gmz130 31769473 · DOI
  16. Lee M. W. Ryu S. Kim D. S. Lee J. W. Sung K. W. Koo H. H. (2019). Mesenchymal Stem Cells in Suppression or Progression of Hematologic Malignancy: Current Status and Challenges. Leukemia 33(3), 597– 611. 10.1038/s41375-018-0373-9 30705410 PMC6756083 · DOI
  17. Lo Cicero A. Stahl P. D. Raposo G. (2015). Extracellular Vesicles Shuffling Intercellular Messages: for Good or for Bad. Curr. Opin. Cel Biol. 35, 69– 77. 10.1016/j.ceb.2015.04.013 26001269 · DOI
  18. Mehdi S. J. Johnson S. K. Epstein J. Zangari M. Qu P. Hoering A. (2019). Mesenchymal Stem Cells Gene Signature in High‐risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐expressing Small Adipocytes. Br. J. Haematol. 184(4), 578– 593. 10.1111/bjh.15669 30408155 PMC6361704 · DOI
  19. Mushahary D. Spittler A. Kasper C. Weber V. Charwat V. (2018). Isolation, Cultivation, and Characterization of Human Mesenchymal Stem Cells. Cytometry 93(1), 19– 31. 10.1002/cyto.a.23242 29072818 · DOI
  20. Nwabo Kamdje A. H. Seke Etet P. F. Simo Tagne R. Vecchio L. Lukong K. E. Krampera M. (2020). Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects. Front. Cel Dev. Biol. 8, 545126. 10.3389/fcell.2020.545126 PMC7710932 33330442 · DOI
  21. O’Brien K. Breyne K. Ughetto S. Laurent L. C. Breakefield X. O. (2020). RNA Delivery by Extracellular Vesicles in Mammalian Cells and its Applications. Nat. Rev. Mol. Cel Biol 21(10), 585– 606. 10.1038/s41580-020-0251-y PMC7249041 32457507 · DOI · Paper page
  22. Palumbo A. Anderson K. (2011). Multiple Myeloma. N. Engl. J. Med. 364(11), 1046– 1060. 10.1056/NEJMra1011442 21410373 · DOI
  23. Pepe F. Visone R. Veronese A. (2018). The Glucose-Regulated MiR-483-3p Influences Key Signaling Pathways in Cancer. Cancers 10(6, 181). 10.3390/cancers10060181 PMC6025222 29867024 · DOI
  24. Qu X. Zhao M. Wu S. Yu W. Xu J. Xu J. (2014). Circulating microRNA 483-5p as a Novel Biomarker for Diagnosis Survival Prediction in Multiple Myeloma. Med. Oncol. 31(10), 219. 10.1007/s12032-014-0219-x 25216866 · DOI
  25. Rattanapan Y. Korkiatsakul V. Kongruang A. Siriboonpiputtana T. Rerkamnuaychoke B. Chareonsirisuthigul T. (2021). High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer. Mirna 10(1), 51– 57. 10.2174/2211536610666210412155206 33845755 · DOI
  26. Ridge S. M. Sullivan F. J. Glynn S. A. (2017). Mesenchymal Stem Cells: Key Players in Cancer Progression. Mol. Cancer 16(1), 31. 10.1186/s12943-017-0597-8 28148268 PMC5286812 · DOI
  27. Roccaro A. M. Sacco A. Maiso P. Azab A. K. Tai Y.-T. Reagan M. (2013). BM Mesenchymal Stromal Cell-Derived Exosomes Facilitate Multiple Myeloma Progression. J. Clin. Invest. 123(4), 1542– 1555. 10.1172/jci66517 23454749 PMC3613927 · DOI
  28. Shah U. A. Mailankody S. (2020). Emerging Immunotherapies in Multiple Myeloma. Bmj 370, m3176. 10.1136/bmj.m3176 32958461 · DOI
  29. Siegel R. L. Miller K. D. Fuchs H. E. Jemal A. (2021). Cancer Statistics, 2021. CA A. Cancer J. Clin. 71(1), 7– 33. 10.3322/caac.21654 33433946 · DOI · Paper page
  30. Stetler-Stevenson W. G. Gavil N. V. (2014). Normalization of the Tumor Microenvironment: Evidence for Tissue Inhibitor of Metalloproteinase-2 as a Cancer Therapeutic. Connect. Tissue Res. 55(1), 13– 19. 10.3109/03008207.2013.867339 24437600 PMC6309251 · DOI
  31. Tian Y. Yan M. Zheng J. Li R. Lin J. Xu A. (2019). miR-483-5p Decreases the Radiosensitivity of Nasopharyngeal Carcinoma Cells by Targeting DAPK1. Lab. Invest. 99(5), 602– 611. 10.1038/s41374-018-0169-6 30664712 · DOI
  32. Umezu T. Imanishi S. Azuma K. Kobayashi C. Yoshizawa S. Ohyashiki K. (2017). Replenishing Exosomes from Older Bone Marrow Stromal Cells with miR-340 Inhibits Myeloma-Related Angiogenesis. Blood Adv. 1(13), 812– 823. 10.1182/bloodadvances.2016003251 29296725 PMC5727805 · DOI
  33. Wang J. Liu L. (2021). MiR-149-3p Promotes the Cisplatin Resistance and EMT in Ovarian Cancer through Downregulating TIMP2 and CDKN1A. J. Ovarian Res. 14(1), 165. 10.1186/s13048-021-00919-5 34798882 PMC8605569 · DOI
  34. Wang X. Han J. Liu Y. Hu J. Li M. Chen X. (2021). miR-17-5p and miR-4443 Promote Esophageal Squamous Cell Carcinoma Development by Targeting TIMP2. Front. Oncol. 11, 605894. 10.3389/fonc.2021.605894 34778021 PMC8579081 · DOI
  35. Wang Z. He J. Bach D.-h. Huang Y.-h. Li Z. Liu H. (2022). Induction of m6A Methylation in Adipocyte Exosomal LncRNAs Mediates Myeloma Drug Resistance. J. Exp. Clin. Cancer Res. 41(1), 4. 10.1186/s13046-021-02209-w 34980213 PMC8722039 · DOI
  36. Weinberg R. A. (2008). Coevolution in the Tumor Microenvironment. Nat. Genet. 40(5), 494– 495. 10.1038/ng0508-494 18443582 · DOI
  37. Willms E. Johansson H. J. Mäger I. Lee Y. Blomberg K. E. M. Sadik M. (2016). Cells Release Subpopulations of Exosomes with Distinct Molecular and Biological Properties. Sci. Rep. 6, 22519. 10.1038/srep22519 26931825 PMC4773763 · DOI
  38. Xu Q. Ye L. Huang L. Zhou L. Chen X. Ye M. (2021). Serum Exosomal miRNA Might Be a Novel Liquid Biopsy to Identify Leptomeningeal Metastasis in Non-small Cell Lung Cancer. Ott Vol. 14, 2327– 2335. 10.2147/ott.S291611 PMC8021268 33833530 · DOI
  39. Zahn L. M. (2017). Effects of the Tumor Microenvironment. Science 355(6332), 12– 1388. 10.1126/science.355.6332.1386-l 28360308 · DOI
  40. Zhao F. Xu Y. Ouyang Y. Wen Z. Zheng G. Wan T. (2021). Silencing of miR-483-5p Alleviates Postmenopausal Osteoporosis by Targeting SATB2 and PI3K/AKT Pathway. Aging 13(5), 6945– 6956. 10.18632/aging.202552 33621956 PMC7993743 · DOI

Cited by

Sorted by citations

Authors
Gu, J., Wang, M., Wang, X., Li, J., Liu, H., Lin, Z., Yang, X., Zhang, X., & Liu, H.
Affiliations
  • Nantong University (CN)
  • Jiangsu University (CN)
  • Affiliated Hospital of Nantong University (CN)
  • First Affiliated Hospital of Soochow University (CN)
Corresponding author
  • Zhang, Xu
  • Liu, Hong
ORCID
Venue
Frontiers in Cell and Developmental Biology
Publisher
Frontiers Media SA
Published
2022-03-01
Volume
10
Pages
862524-862524
ISSN
2296-634X (ISSN-L)
DOI
10.3389/fcell.2022.862524
PMC
PMC8921260
OpenAlex
W4214711818
Cited by
27
References
2
Citations by year
2026: 2 · 2025: 9 · 2024: 3 · 2023: 12 · 2022: 1
FWCI
4.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Nantong Science and Technology Bureau
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
multiple myeloma, bone marrow mesenchymal stem cells, exosomes, miR-483-5p, TIMP-2, tumor microenvironment, malignant progression, cell proliferation, apoptosis, tumor suppressor, exosomal microRNAs, biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review